AZN vs IMNM: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
AZN is the larger of the two ($272.37B market cap): the incumbent the market prices for continued execution (15.52x forward earnings, beta 0.16). IMNM is the smaller challenger ($1.90B), still expected to post a loss next year: more room to run, but more to prove. On the numbers, AZN leads on both counts: faster expected revenue growth (6% vs 0%) and expected profits next year, which IMNM does not have. The case for IMNM rests on its own driver (Varegacestat FDA decision and launch): if you believe in that, IMNM fits; if you believe in what the numbers show today, AZN does.
AZN vs IMNM: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AZN | IMNM | What it tells you |
|---|---|---|---|
| Market cap | $272.37B | $1.90B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 15.52 | -6.21 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.16 | 2.66 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 37% of range | 0% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.27 | 4.02 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how AZN and IMNM affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AZN and IMNM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AZN and IMNM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does AstraZeneca (AZN) do?
AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. It develops and sells prescription medicines across four main areas: oncology (its biggest engine), cardiovascular-renal-metabolism, respiratory and immunology, and rare disease through Alexion, which it acquired in 2021. Flagship products include the cancer drugs Tagrisso, Imfinzi, Calquence, Lynparza (partnered with Merck) and Enhertu (partnered with Daiichi Sankyo), plus the diabetes and heart-failure drug Farxiga and rare-disease therapies like Ultomiris and Soliris. In 2025 the company reported total revenue of about $58.7 billion, up roughly 9%, and it has set a public ambition to grow that to $80 billion by 2030, with about half expected to come from the United States.
What does Immunome (IMNM) do?
Immunome, Inc. is a Nasdaq-listed, clinical-stage targeted-oncology company developing cancer therapies. Its lead asset is varegacestat, a once-daily oral gamma secretase inhibitor for adults with progressing desmoid tumors; the company submitted a New Drug Application to the U.S. FDA in April 2026, the FDA accepted it in July 2026 with a PDUFA target action date of April 28, 2027, and the European Medicines Agency validated a marketing authorization application in October 2026, both backed by the Phase 3 RINGSIDE trial that showed an ~84% reduction in the risk of disease progression or death and a ~56% confirmed objective response rate versus ~9% for placebo. Behind that lead program sits an antibody-drug-conjugate (ADC) and radiotherapy pipeline, including IM-1021 (a ROR1 ADC), IM-3050 (a FAP-targeted radiotherapy), IM-1617, and additional preclinical candidates. IM-1617 dosed its first patient in June 2026 and IM-3050 in July 2026, and on 30 September 2026 the FDA cleared the IND for IM-1340, a potential first-in-class ADC for solid tumors, with a Phase 1 start expected by the end of 2026. Updated IM-1021 data in B-cell lymphomas is due at the ASH annual meeting on December 14, 2026; at a June 2026 data cutoff the drug had a 64% objective response rate (7 of 11) in diffuse large B-cell lymphoma.
AZN vs IMNM: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- AZN drivers: Oncology franchise and the $80 billion ambition; Deep late-stage pipeline.
- IMNM drivers: Varegacestat FDA decision and launch; ADC and radiotherapy pipeline.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. For IMNM, as a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock.
AZN or IMNM: which should you pick?
If the story you believe is AZN's (Oncology franchise and the $80 billion ambition), AZN is the more direct way to own it; if it is IMNM's (Varegacestat FDA decision and launch), IMNM is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AZN and IMNM guides.
AZN vs IMNM: the full fundamentals
AZN. AstraZeneca trades at about 25 times trailing reported earnings but about 15.5 times forward earnings, a gap that reflects heavy amortisation and one-off charges in reported profit and consensus for 2026 EPS near $10.12 rising to about $11.32 in 2027. The forward multiple has edged up from about 14.6 in October as the shares recovered, but it still sits near the low end of where a growth-oriented large-cap pharma usually trades, so the valuation reflects more caution about the 2032 patent cliff than enthusiasm for the $80 billion 2030 goal. Figures are approximate and tied to the asOf date; confirm live numbers before acting.
IMNM. Immunome trades on pipeline expectations, not profits, so earnings multiples do not apply to a company with no current revenue and a trailing loss near $283 million. Its roughly $1.9 billion market value, down from about $2.0 billion in mid-October and $2.6 billion in July 2026, is the market's probability-weighted view of an April 2027 varegacestat approval plus the ADC pipeline, set against about $462 million of cash. Consensus expects losses of roughly $2.52 per share in 2026 and $2.59 in 2027, and analysts carry a strong buy consensus with a mean target near $35.
Headline figures (approximate, November 2026): AZN shows revenue (ttm) About $62.4 billion; Q3 2026 revenue about $16.2 billion, up roughly 7% year over year, net income (ttm) About $11.0 billion, a net margin near 18%, with gross margin near 82% and operating margin near 26%, eps Q3 2026 EPS $1.00 vs about $1.15 expected; trailing reported EPS about $7.07, p/e About 25x trailing reported earnings, about 15.5x forward; IMNM shows market cap ~$1.9B, share price ~$16.08 (20 November 2026); 52-week range ~$16.08 to ~$30.06, revenue None in Q2 or Q3 2026; ~$7M in FY2025; 2027 consensus ~$49M, cash, equivalents and marketable securities (september 2026) ~$462M, runway into 2028 per the company; debt ~$11M.
The bottom line: AZN vs IMNM
AZN and IMNM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined AZN and IMNM exposure against your real portfolio. It is not an investment adviser.
Wondering how AZN or IMNM fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about AstraZeneca
Ask Walnut's AI anything about AZN and see how it fits what you own.
FAQ
What is the difference between AZN and IMNM?
+
AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. Immunome, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AZN or IMNM the better stock?
+
Neither is universally better. AZN is the larger incumbent; IMNM is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AZN or IMNM?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AZN and IMNM?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AZN vs IMNM?
+
AZN: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. Generic and biosimilar erosion is already visible, with first generics to Farxiga cleared in 2026. Pipeline risk is constant, since late-stage trial failures such as a disappointing AVANZAR result can erase billions in expected value quickly. China, about a tenth of revenue, carries added uncertainty after the company's former China head was indicted in a compliance case that drew investor lawsuits. Drug pricing policy, US tariffs and currency swings add further volatility, and the balance sheet carries about $34 billion of debt against about $8 billion of cash. As a large-cap pharma the stock can still fall sharply on a single disappointing readout or regulatory decision, as its slide from a 52-week high near $213 to a low near $153 shows. The Q3 2026 EPS shortfall against consensus is a reminder that quarterly earnings can disappoint even as revenue grows. IMNM: As a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. The company has minimal product revenue and posts recurring net losses that keep growing (about $85.8 million in Q3 2026, up from $73.1 million in Q2 and $57.5 million a year earlier), so it depends on its cash balance and, potentially, future capital raises that could dilute shareholders. Even with approval, commercial uptake is uncertain because an established oral competitor already serves the desmoid market. Pipeline candidates are early and most drug programs fail in development, and IM-1021's safety profile (grade 3 or higher events in about half of treated patients) will be watched at ASH. The shares are volatile and can move sharply on single trial, regulatory, or insider-selling headlines: they fell about 45% over the three months to 20 November 2026 and closed at a 52-week low. Analyst views have diverged: Stifel initiated at Hold with a $24 target in October while William Blair initiated at Outperform, and the 15 analysts tracked by Yahoo Finance average a target near $35.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AZN or IMNM; figures are approximate and dated (as of November 2026). Verify current data before investing.